Logo image of CTSO

CYTOSORBENTS CORP (CTSO) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:CTSO - US23283X2062 - Common Stock

0.6894 USD
-0.01 (-1.51%)
Last: 12/24/2025, 8:22:53 PM
Fundamental Rating

2

Taking everything into account, CTSO scores 2 out of 10 in our fundamental rating. CTSO was compared to 185 industry peers in the Health Care Equipment & Supplies industry. CTSO has a bad profitability rating. Also its financial health evaluation is rather negative. CTSO is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CTSO had negative earnings in the past year.
In the past year CTSO has reported a negative cash flow from operations.
In the past 5 years CTSO always reported negative net income.
CTSO had a negative operating cash flow in each of the past 5 years.
CTSO Yearly Net Income VS EBIT VS OCF VS FCFCTSO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

CTSO's Return On Assets of -23.14% is in line compared to the rest of the industry. CTSO outperforms 51.35% of its industry peers.
CTSO has a Return On Equity of -117.35%. This is in the lower half of the industry: CTSO underperforms 64.32% of its industry peers.
Industry RankSector Rank
ROA -23.14%
ROE -117.35%
ROIC N/A
ROA(3y)-50.29%
ROA(5y)-37.4%
ROE(3y)-134.62%
ROE(5y)-90.6%
ROIC(3y)N/A
ROIC(5y)N/A
CTSO Yearly ROA, ROE, ROICCTSO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800

1.3 Margins

CTSO has a Gross Margin of 77.02%. This is amongst the best in the industry. CTSO outperforms 88.65% of its industry peers.
CTSO's Gross Margin has been stable in the last couple of years.
CTSO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 77.02%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.74%
GM growth 5Y0.03%
CTSO Yearly Profit, Operating, Gross MarginsCTSO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

2

2. Health

2.1 Basic Checks

CTSO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CTSO has been increased compared to 1 year ago.
Compared to 5 years ago, CTSO has more shares outstanding
The debt/assets ratio for CTSO is higher compared to a year ago.
CTSO Yearly Shares OutstandingCTSO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
CTSO Yearly Total Debt VS Total AssetsCTSO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -8.67, we must say that CTSO is in the distress zone and has some risk of bankruptcy.
CTSO has a worse Altman-Z score (-8.67) than 78.92% of its industry peers.
A Debt/Equity ratio of 1.61 is on the high side and indicates that CTSO has dependencies on debt financing.
CTSO has a Debt to Equity ratio of 1.61. This is in the lower half of the industry: CTSO underperforms 79.46% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.61
Debt/FCF N/A
Altman-Z -8.67
ROIC/WACCN/A
WACC9.14%
CTSO Yearly LT Debt VS Equity VS FCFCTSO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

A Current Ratio of 2.11 indicates that CTSO has no problem at all paying its short term obligations.
CTSO's Current ratio of 2.11 is on the low side compared to the rest of the industry. CTSO is outperformed by 60.54% of its industry peers.
A Quick Ratio of 1.71 indicates that CTSO should not have too much problems paying its short term obligations.
CTSO's Quick ratio of 1.71 is in line compared to the rest of the industry. CTSO outperforms 45.41% of its industry peers.
Industry RankSector Rank
Current Ratio 2.11
Quick Ratio 1.71
CTSO Yearly Current Assets VS Current LiabilitesCTSO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 51.35% over the past year.
Looking at the last year, CTSO shows a decrease in Revenue. The Revenue has decreased by -8.97% in the last year.
CTSO shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 7.36% yearly.
EPS 1Y (TTM)51.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25%
Revenue 1Y (TTM)-8.97%
Revenue growth 3Y-6.23%
Revenue growth 5Y7.36%
Sales Q2Q%1.01%

3.2 Future

The Earnings Per Share is expected to grow by 32.93% on average over the next years. This is a very strong growth
CTSO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 26.86% yearly.
EPS Next Y59.74%
EPS Next 2Y36.1%
EPS Next 3Y32.93%
EPS Next 5YN/A
Revenue Next Year-3.82%
Revenue Next 2Y2.75%
Revenue Next 3Y9.46%
Revenue Next 5Y26.87%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CTSO Yearly Revenue VS EstimatesCTSO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M
CTSO Yearly EPS VS EstimatesCTSO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CTSO. In the last year negative earnings were reported.
Also next year CTSO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CTSO Price Earnings VS Forward Price EarningsCTSO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CTSO Per share dataCTSO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4

4.3 Compensation for Growth

A more expensive valuation may be justified as CTSO's earnings are expected to grow with 32.93% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.1%
EPS Next 3Y32.93%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CTSO!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

CYTOSORBENTS CORP

NASDAQ:CTSO (12/24/2025, 8:22:53 PM)

0.6894

-0.01 (-1.51%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-13 2025-11-13/amc
Earnings (Next)01-01 2026-01-01/amc
Inst Owners26.2%
Inst Owner Change-0.07%
Ins Owners9.21%
Ins Owner Change2.8%
Market Cap43.29M
Revenue(TTM)34.35M
Net Income(TTM)-10.59M
Analysts80
Price Target5.48 (694.89%)
Short Float %3.8%
Short Ratio18.72
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)76.89%
Min EPS beat(2)-5.03%
Max EPS beat(2)158.82%
EPS beat(4)2
Avg EPS beat(4)27.26%
Min EPS beat(4)-116.73%
Max EPS beat(4)158.82%
EPS beat(8)6
Avg EPS beat(8)21.99%
EPS beat(12)7
Avg EPS beat(12)13.46%
EPS beat(16)7
Avg EPS beat(16)-7.04%
Revenue beat(2)1
Avg Revenue beat(2)-2.61%
Min Revenue beat(2)-7.32%
Max Revenue beat(2)2.1%
Revenue beat(4)1
Avg Revenue beat(4)-5.35%
Min Revenue beat(4)-11.18%
Max Revenue beat(4)2.1%
Revenue beat(8)2
Avg Revenue beat(8)-5.15%
Revenue beat(12)4
Avg Revenue beat(12)-4.39%
Revenue beat(16)5
Avg Revenue beat(16)-5.31%
PT rev (1m)0.78%
PT rev (3m)7.5%
EPS NQ rev (1m)0%
EPS NQ rev (3m)14.29%
EPS NY rev (1m)3.23%
EPS NY rev (3m)-15.38%
Revenue NQ rev (1m)-7.55%
Revenue NQ rev (3m)-11.25%
Revenue NY rev (1m)-4.17%
Revenue NY rev (3m)-4.17%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.26
P/FCF N/A
P/OCF N/A
P/B 4.8
P/tB 7.98
EV/EBITDA N/A
EPS(TTM)-0.18
EYN/A
EPS(NY)-0.06
Fwd EYN/A
FCF(TTM)-0.16
FCFYN/A
OCF(TTM)-0.16
OCFYN/A
SpS0.55
BVpS0.14
TBVpS0.09
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -23.14%
ROE -117.35%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 77.02%
FCFM N/A
ROA(3y)-50.29%
ROA(5y)-37.4%
ROE(3y)-134.62%
ROE(5y)-90.6%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.74%
GM growth 5Y0.03%
F-Score4
Asset Turnover0.75
Health
Industry RankSector Rank
Debt/Equity 1.61
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 15.94%
Cap/Sales 0.71%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.11
Quick Ratio 1.71
Altman-Z -8.67
F-Score4
WACC9.14%
ROIC/WACCN/A
Cap/Depr(3y)280.25%
Cap/Depr(5y)336.32%
Cap/Sales(3y)7.84%
Cap/Sales(5y)7.51%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)51.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25%
EPS Next Y59.74%
EPS Next 2Y36.1%
EPS Next 3Y32.93%
EPS Next 5YN/A
Revenue 1Y (TTM)-8.97%
Revenue growth 3Y-6.23%
Revenue growth 5Y7.36%
Sales Q2Q%1.01%
Revenue Next Year-3.82%
Revenue Next 2Y2.75%
Revenue Next 3Y9.46%
Revenue Next 5Y26.87%
EBIT growth 1Y32.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year28.96%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y52.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y51.53%
OCF growth 3YN/A
OCF growth 5YN/A

CYTOSORBENTS CORP / CTSO FAQ

What is the fundamental rating for CTSO stock?

ChartMill assigns a fundamental rating of 2 / 10 to CTSO.


What is the valuation status for CTSO stock?

ChartMill assigns a valuation rating of 1 / 10 to CYTOSORBENTS CORP (CTSO). This can be considered as Overvalued.


How profitable is CYTOSORBENTS CORP (CTSO) stock?

CYTOSORBENTS CORP (CTSO) has a profitability rating of 1 / 10.


What is the financial health of CYTOSORBENTS CORP (CTSO) stock?

The financial health rating of CYTOSORBENTS CORP (CTSO) is 2 / 10.